Active ingredientBleomycin SulfateCat. No. P-B093-001CAS 9041-93-4Family · Pharmaceutical analytical standards
Bleomycin
An anticancer antibiotic discovered in Japan in the 1960s by Hamao Umezawa in the bacterium Streptomyces verticillus and approved in the United States in 1973: it is used for testicular and ovarian cancer and Hodgkin lymphoma. This family brings together the active ingredient and pharmacopoeial impurities.
Did you know?During fermentation the bacterium makes it bound to a copper atom, in a blue-coloured form; inside cells it binds mainly to iron instead and, with the help of oxygen, breaks DNA.
Go to the active ingredient →Active ingredientBleomycin SulfateCat. No. P-B093-001CAS 9041-93-4
Pharmacopoeial impurityBleomycin EP Impurity ACat. No. P-B093-002CAS 37364-66-2
Pharmacopoeial impurityBleomycin EP Impurity BCat. No. P-B093-003CAS 11116-32-8
Pharmacopoeial impurityBleomycin EP Impurity CCat. No. P-B093-004CAS 9060-11-1
Pharmacopoeial impurityBleomycin EP Impurity DCat. No. P-B093-005CAS 41089-03-6No product matches your search.
EDQM standards 1
The official European Pharmacopoeia standards for this family.
Reference substanceBleomycin sulfate CRSEDQM code B1141000Family BleomycinNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.